Loading...
NPI 1902944002 · Newport, VT · Substance Use Disorder Rehabilitation Clinic/Center
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Baart Behavioral Health Services, Inc. is a substance use disorder rehabilitation clinic/center provider located in Newport, Vermont. This profile covers 2 Medicare and 9 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Baart Behavioral Health Services, Inc. |
| Address | 475 Union St |
| City | Newport |
| State | VT |
| ZIP | 05855 |
| Taxonomy | Substance Use Disorder Rehabilitation Clinic/Center |
| NPI Enumerated | February 1, 2007 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $17.6M |
| Medicare | $85.8K |
BAART BEHAVIORAL HEALTH SERVICES, INC. is operating as a substance use disorder rehabilitation clinic/center that bills like an opioid treatment program: Medicare top code G2067 is the weekly methadone bundle (dispensing/administration, counseling, group and individual therapy, toxicology testing), and Medicaid top codes include H0020 for methadone administration plus multiple buprenorphine NDC codes (J0575, J0574, J0572, J0573) that reflect on-site medication dispensing and ongoing medication-assisted treatment (MAT). The code mix points to a service model built around high-volume medication dispensing combined with counseling and toxicology services rather than primarily office-based evaluation and management visits.
This provider is effectively Medicaid-dominant: lifetime Medicare revenue is $85.8K while lifetime Medicaid revenue is $17.6M, indicating the vast majority of its billed services and reimbursement flow through Medicaid rather than Medicare. Analysts should treat Medicaid performance as the primary lens for competitive and operational assessment.
Medicare revenue is highly concentrated: the precomputed top-3 Medicare codes account for 100.0% of this provider's Medicare revenue, with G2067 alone representing $82.9K or 96.6% of Medicare revenue and G2078 representing $2.9K or 3.4% of Medicare revenue. Despite this concentration, G2067 volumes are described as "typical, unremarkable" nationally (ranks #669 of 830, 19th percentile) and G2078 is also labeled "typical, unremarkable" (rank #484 of 493, 2th percentile), so the Medicare presence is real but modest compared with national OTPs.
Medicaid revenue is also highly concentrated: the precomputed top-3 Medicaid codes account for 97.6% of Medicaid revenue, with H0020 generating $15M or 85.2% of Medicaid revenue and two buprenorphine product codes, J0575 ($1.1M, 6.2%) and J0574 ($1.1M, 6.1%), accounting for the next-largest shares. H0020 is characterized as a typical, unremarkable in-state volume (rank #3 of 9, 75th percentile), while J0575 and J0574 are labeled "notably above typical state volume" (each rank #1 of 7, 100th percentile), showing a clear split between a strong methadone program and an outsized role in buprenorphine dispensing.
On statewide competitive standing, the provider appears to be a leading source of buprenorphine in Vermont (J0575, J0574, and J0572 all rank #1 of 7, 100th percentile and are described as notably above typical), indicating a dominant or specialty role for buprenorphine-based MAT in the state. By contrast, for methadone administration (H0020) the provider ranks #3 of 9 (75th percentile), meaning it is an important but not sole dominant methadone provider in-state.
Operational scale is reflected in claim counts: the provider reports 42.2K H0020 claims and very large counts for buprenorphine codes (J0575 57.5K claims, J0574 89.9K claims), which together indicate sustained, high-throughput medication dispensing and repeat treatment visits. E/M codes such as 99214 (96 claims, $10K) and 99213 (638 claims, $638) represent only a tiny fraction of Medicaid revenue, reinforcing that revenue is driven by medication and OTP-specific bundles rather than routine outpatient evaluation visits.
The provider’s financial profile creates both concentration risk and strategic opportunity: Medicaid top-3 codes account for 97.6% of Medicaid revenue and H0020 alone is 85.2% of Medicaid revenue, so changes in methadone reimbursement or state program policy could materially affect revenue. Conversely, the provider’s top-ranked position on multiple buprenorphine codes (100th percentile, notably above typical) suggests an opportunity to leverage that leadership for broader MOUD services, care coordination, or payer contracting focused on buprenorphine access.
BAART’s NPI has been enumerated since 2007-02-01 (~19 years ago), indicating long tenure in the market; combined with $17.6M lifetime Medicaid revenue and sizable claim volumes, this points to an established operational footprint in Vermont’s substance use disorder treatment landscape. Analysts should interpret current billing patterns as the product of sustained OTP operations rather than a short-term or newly scaled program.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
2 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G2067 | Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed… | 380 | $220 | $82.9K |
| G2078 | Take-home supply of methadone; up to 7 additional day supply (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure | 70 | $40 | $2.9K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 2 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
9 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | 42,170 | $360 | $15M |
| J0575 | Buprenorphine/naloxone, oral, greater than 10 mg buprenorphine | 57,510 | $20 | $1.1M |
| J0574 | Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine | 89,890 | $10 | $1.1M |
| J0572 | Buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphine | 44,590 | $10 | $222.9K |
| H0047 | Alcohol and/or other drug abuse services, not otherwise specified | 1,060 | $90 | $95.3K |
| J0573 | Buprenorphine/naloxone, oral, greater than 3 mg, but less than or equal to 6 mg buprenorphine | 10,270 | $10 | $92.4K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 100 | $100 | $10K |
| G2067 | Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed… | 100 | $20 | $1.7K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 640 | $1 | $640 |
How this provider's Medicaid billing volume and revenue compare to other Vermont providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Vermont median
9 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | 3 | 10 | 17,110 | $40 | $13.6M |
| G2067 | Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed… | 6 | 10 | 120 | $190 | $4.1M |
| J0575 | Buprenorphine/naloxone, oral, greater than 10 mg buprenorphine | 1 | 10 | 1,360 | $50 | $551.1K |
| J0574 | Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine | 1 | 10 | 6,550 | $30 | $483.4K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 257 | 320 | 680 | $30 | $146.1K |
| J0572 | Buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphine | 1 | 10 | 1,470 | $10 | $107.9K |
| J0573 | Buprenorphine/naloxone, oral, greater than 3 mg, but less than or equal to 6 mg buprenorphine | 1 | 10 | 3,890 | $20 | $101.4K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 169 | 320 | 760 | $20 | $88.2K |
| H0047 | Alcohol and/or other drug abuse services, not otherwise specified | 1 | 10 | 190 | $90 | $37.7K |
Other providers in the same ZIP code as Baart Behavioral Health Services, Inc., ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.